Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 16, 2016 - Issue 11
Submit an article Journal homepage
431
Views
7
CrossRef citations to date
0
Altmetric
Review

No evidence of disease activity in multiple sclerosis patients

André Palma da Cunha MattaNeurology Department, Federal Fluminense University, Rio de Janeiro, BrazilCorrespondence[email protected]
,
Osvaldo J. M. NascimentoNeurology Department, Federal Fluminense University, Rio de Janeiro, Brazil
,
Ana Carolina Andorinho de F. FerreiraNeurology Department, Federal Fluminense University, Rio de Janeiro, Brazil
,
Thaís Nascimento MagalhãesNeurology Department, Federal Fluminense University, Rio de Janeiro, Brazil
,
Taís Pais Resende BenevidesNeurology Department, Federal Fluminense University, Rio de Janeiro, Brazil
,
Arielle KirmseNeurology Department, Federal Fluminense University, Rio de Janeiro, Brazil
,
Joao Gabriel DibNeurology Department, Federal Fluminense University, Rio de Janeiro, Brazil
,
Henrique CalNeurology Department, Federal Fluminense University, Rio de Janeiro, Brazil
,
Marco OrsiniNeurology Department, Federal Fluminense University, Rio de Janeiro, Brazil;Faculty of Medicine, Severino Sombra University, Vassouras, Brazil
&
Lucas Masiêro AraujoNeurology Department, Federal Fluminense University, Rio de Janeiro, Brazil
 show all
Pages 1279-1284 | Received 02 Mar 2016, Accepted 14 Jun 2016, Published online: 07 Jul 2016

References

  • Lublin F, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis. The 2013 revisions. Neurology. 2014;83:278–286.
  • Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502–1517.
  • Bermel RA, You X, Foulds P, et al. Predictors of long-term outcome in multiple sclerosis patients treated with interferon β. Ann Neurol. 2013;73:95–103.
  • Bevan CJ, Cree BC. Disease activity free status: a new end point for a new era in multiple sclerosis clinical research?. JAMA Neurol. 2014;71(3):269–270. doi:10.1001/jamaneurol.2013.5486.
  • Giovannoni G, Turner B, Gnanapavan S, et al. Is it time to target no evident disease activity (NEDA) in multiple sclerosis? Mult Scler Relat Disord. 2015;4:329–333.
  • Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) Study. Lancet Neurol. 2009;8(3):254–260.
  • Rotstein DL, Healy BC, Malik MT, et al. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol. 2015;72(2):152–158.
  • Kappos L, De Stefano N, Freedman MS, et al. Inclusion of brain volume loss in a revised measure of no 'evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis. Mult Scler. 2015. doi:10.1177/1352458515616701
  • Havrdova E, Galetta S, Stefoski D, et al. Freedom from disease activity in multiple sclerosis. Neurology Suppl. 2010;74:S3–S7.
  • Ziemssen T, Derfuss T, de Stefano N, et al. Optimizing treatment success in multiple sclerosis. J Neurol. 2016;263(6):1053–1065.
  • Banwell B, Giovannoni G, Hawkes C, et al. Editors’ welcome and a working definition for a multiple sclerosis cure. Mult Scler Relat Disord. 2013;2:65–67.
  • Freedman MS. Are we in need of NEDA? Mult Scler. 2016;22:5–6.
  • Chaudhuri A, Behan PO. Lessons from clinical trials of alemtuzumab in multiple sclerosis. Mult Scler Relat Disord. 2013;2(2):92–95.
  • Bakshi R, Shaikh ZA, Miletich RS, et al. Fatigue in multiple sclerosis and its relationship to depression and neurologic disability. Mult Scler. 2000;6:181–185.
  • Miletic S, Toncev G, Jevdjic J, et al. Fatigue and depression in multiple sclerosis: correlation with quality of life. Arch Biol Sci Belgrade. 2011;63(3):617–622.
  • Hayter AL, Salkovskis PM, Silber E, et al. The impact of health anxiety in patients with relapsing remitting multiple sclerosis: Misperception, misattribution and quality of life. Br J Clin Psychol. 2016. doi:10.1111/bjc.12106
  • Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69:292–302.
  • MAGNIMS study group. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. Nat Rev Neurol. 2015;11:471–482.
  • MAGNIMS study group. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis — establishing disease prognosis and monitoring patients. Nat Rev Neurol. 2015;11:597–606.
  • Wattjes MP, Steenwijk MD, Stangel M. MRI in the diagnosis and monitoring of multiple sclerosis: an update. Clin Neuroradiol. 2015;25(2):157–165.
  • Stangel M, Penner IK, Kallmann BA, et al. Towards the implementation of ‘no evidence of disease activity’ in multiple sclerosis treatment: the multiple sclerosis decision model. Ther Adv Neurol Disord. 2015;8:3–13.
  • Zivadinov R, Dwyer M, Barkay H, et al. Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense ‘black holes’: a post hoc magnetic resonance imaging analysis. J Neurol. 2015;262(3):648–653.
  • Nygaard GO, Celius EG, de Rodez Benavent SA, et al. A longitudinal study of disability, cognition and gray matter atrophy in early multiple sclerosis patients according to evidence of disease activity. PLoS ONE. 2015;10:e0135974.
  • Zivadinov R, Reder AT, Filippi M, et al. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology. 2008;71:136–144.
  • De Stefano N, Airas L, Grigoriadis N, et al. Clinical relevance of brain volume measures in multiple sclerosis. CNS Drugs. 2014;28(2):147–156.
  • Arnold DL, Li D, Hohel M, et al. Evolving role of MRI in optimizing the treatment of multiple sclerosis: Canadian consensus recommendations. Mult Scler J. 2015;1:1–9.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.